The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients

作     者：Wen-Xiong Xu Yang-Mei Li Jian-Guo Li Yong-Yu Mei You-Ming Chen Xue-Jun Li Chao-Shuang Lin Hong Deng Zhi-Xin Zhao Dong-Ying Xie Zhi-Liang Gao Liang Peng 

作者机构：Department of Infectious DiseasesThe Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdongP.R.China Guangdong Key Laboratory of Liver Disease ResearchThe Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdongP.R.China Department of Prevention and Health CareThe Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdongP.R.China 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2021年第9卷第4期

页      面：313-322,I0002页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by grants from Natural Science Foundation of China National Major Science and Technology Project for the Prevention and Treatment of AIDS and viral hepatitis the Five-Year Plan of the Third Affiliated Hospital of Sun Yat-sen University 

主　　题：chronic hepatitis B nucleos(t)ide analogs cessation relapse hepatitis B virus 

摘      要：Background:Chronic hepatitis B(CHB)patients have a high virological relapse rate after cessation of nucleos(t)ide analog(NA)treatment,but the clinical outcome remains *** study aimed to investigate the 96-week clinical outcomes and the risk factors for relapse in CHB after cessation of ***:This study was a prospective trial;74 eligible patients were *** patients underwent NA cessation and follow-up according to the 2012 Asian Pacific Association for the Study of the Liver ***,biochemical(aspartate aminotransferase[AST],alanine aminotransferase[ALT],total bilirubin,urea nitrogen,creatinine),virological data(hepatitis B surface antigen[HBsAg],hepatitis B e antigen[HBeAg],hepatitis B e antibody[HBeAb],hepatitis B virus[HBV]DNA levels),and color Doppler ultrasound examination results were recorded and ***:After NA cessation,19 cases were HBsAg-negative without relapse during the 96-week *** the 55 cases of HBsAg-positive after cessation,four types of clinical outcomes were *** patients had no relapse during the 96-week follow-up(type A,21.8%),7 patients underwent virological relapses but spontaneously had a non-virological relapse(type B,12.7%),10 patients maintained virological relapse(type C,18.2%),and 26 patients turned to clinical relapse,received NA retreatment,and achieved ALT normalization and negative conversion of HBV DNA within 12 months(type D,47.3%).The 2-year overall cumulative rates of virological and clinical relapses were 58.1%and 24.3%,*** factors associated with virological relapse were duration of negative HBV DNA,EOT(end of treatment)HBsAg,and original status of *** EOT HBsAg was also an independent factor for clinical ***:There are four types of clinical outcomes in patients with CHB after cessation of NA *** research is needed to explore the mechanism of different clinical *** EOT HBsAg level is an independent